Recombinant Anti-CD19 x Anti-CD3 Bispecific Antibody (Triple Body) is designed to be expressed as two polypeptide chains respectively. The Fd fragment and LC from an anti-CD19 antibody are both extended with the scFv fragment from an anti-CD3 antibody. This BsAb can retarget T cells to tumor cells. It is designed for the research of B cell lymphoma; Follicular lymphoma; Leukemia therapy.
Welcome! For price inquiries, we will get back to you as soon as possible.
INQUIRY